ALKS vs GKOS: Which Stock Is the Better Buy?
Alkermes plc and Glaukos Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ALKS vs GKOS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Alkermes plc (ALKS) | Glaukos Corporation (GKOS) | |
|---|---|---|
| Market cap | $7.3B | $7.2B |
| Revenue (latest FY) | $1.48B | $507.44M |
| Net income (latest FY) | $241.66M | $-187.69M |
| Revenue growth (5y CAGR) | 7.3% | 17.7% |
| Net margin | 16.4% | -37.0% |
| Return on equity | 13.3% | -28.6% |
| P/E ratio | 49.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 2 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ALKS vs GKOS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ALKS's full financials → Open GKOS's full financials →More comparisons
Frequently asked questions
Which is bigger, ALKS or GKOS?
Alkermes plc is larger by market capitalization — $7.3B versus $7.2B.
Which grows faster, ALKS or GKOS?
Over the last five fiscal years, Glaukos Corporation grew revenue faster — 17.7%/yr versus 7.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ALKS fundamentals → · GKOS fundamentals → · All 1,500+ companies → · Free screener →